Copy For Citation
Ozturk-Cerik H., Esen S., ALTINTAŞ ÖNER B., Celik M., Ozdemir T., TANYEL E.
KLIMIK JOURNAL, vol.33, no.3, pp.297-306, 2020 (ESCI)
Article / Article
Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database
Hepatitis C, sofosbuvir, ledipasvir, ombitasvir, paritaprevir, dasabuvir, VIRUS GENOTYPE 1, 4 INFECTION, RIBAVIRIN, EFFICACY, LEDIPASVIR/SOFOSBUVIR, SOFOSBUVIR, SAFETY
Eskisehir Osmangazi University Affiliated:
Objective: Hepatitis C virus (HCV) infection is a global problem with personal, social and economic impacts. Approximately 85% of patients infected with HCV cannot achieve virus clearance. Cirrhosis, hepatocellular carcinoma and death may develop in patients with chronic infection.Until recently, treatments for chronic hepatitis C were difficult to use with many side effects, low treatment responses, and relapses. Direct-acting antivirals (DAAs) prevent HCV replication, and thir effectiveness is over 90%. In this study, we aimed to evaluate the achievement of these treatments.